Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2007

Open Access 01-12-2007 | Original Paper

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population

Authors: Dewajani Purnomosari, Gerard Pals, Artanto Wahyono, Teguh Aryandono, Tjakra W. Manuaba, Samuel J. Haryono, Paul J. van Diest

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access

Abstract

Specific mutations in BRCA1 and BRCA2 genes have been identified in specific populations and ethnic groups. However, little is known about the contribution of BRCA1 and BRCA2 mutations to breast cancers in the Indonesian population. One hundred-twenty moderate to high risk breast cancer patients were tested using PCR-DGGE, and any aberrant band was sequenced. Multiplex ligation-dependent probe amplification (MLPA) was performed on all samples to detect large deletions in the two genes. Twenty-three different mutations were detected in 30 individuals, ten were deleterious mutations and 20 were “unclassified variants” with uncertain clinical consequences. Three of seven (c.2784_2875insT, p.Leu1415X and del exon 13–15) and two of four (p.Glu2183X and p.Gln2894X) deleterious mutations that were found in BRCA1 and BRCA2 respectively, are novel. Several novel, pathogenic BRCA1 and BRCA2 germline mutations are found in early onset Indonesian breast cancer patients, these may therefore be specific for the Indonesian population.
Literature
1.
go back to reference Easton D, Peto J (1990) The contribution of inherited predisposition to cancer incidence. Cancer Surv 9(3):395–416PubMed Easton D, Peto J (1990) The contribution of inherited predisposition to cancer incidence. Cancer Surv 9(3):395–416PubMed
2.
go back to reference Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324CrossRefPubMed Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324CrossRefPubMed
3.
go back to reference Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684–1689CrossRefPubMed Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684–1689CrossRefPubMed
4.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed
5.
go back to reference Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed
6.
go back to reference Scully R, Livingston DM (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408(6811):429–432CrossRefPubMed Scully R, Livingston DM (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408(6811):429–432CrossRefPubMed
7.
go back to reference Zheng L, Li S, Boyer TG, Lee WH (2000) Lessons learned from BRCA1 and BRCA2. Oncogene 19(53):6159–6175CrossRefPubMed Zheng L, Li S, Boyer TG, Lee WH (2000) Lessons learned from BRCA1 and BRCA2. Oncogene 19(53):6159–6175CrossRefPubMed
8.
go back to reference Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121CrossRefPubMed Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121CrossRefPubMed
9.
go back to reference Stratton MR, Wooster R (1996) Hereditary predisposition to breast cancer. Curr Opin Genet Dev 6(1):93–97CrossRefPubMed Stratton MR, Wooster R (1996) Hereditary predisposition to breast cancer. Curr Opin Genet Dev 6(1):93–97CrossRefPubMed
10.
go back to reference Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M et al (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 273(7):535–541CrossRefPubMed Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M et al (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 273(7):535–541CrossRefPubMed
11.
go back to reference Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242–1250CrossRefPubMed Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242–1250CrossRefPubMed
12.
go back to reference Monteiro AN, August A, Hanafusa H (1997) Common BRCA1 variants and transcriptional activation. Am J Hum Genet 61(3):761–762PubMed Monteiro AN, August A, Hanafusa H (1997) Common BRCA1 variants and transcriptional activation. Am J Hum Genet 61(3):761–762PubMed
13.
go back to reference Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2):185–187CrossRefPubMed Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2):185–187CrossRefPubMed
14.
go back to reference Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Belanger C, Dion F et al (1994) Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8(4):392–398CrossRefPubMed Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Belanger C, Dion F et al (1994) Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8(4):392–398CrossRefPubMed
15.
go back to reference Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60(5):1041–1049PubMed Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E et al (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60(5):1041–1049PubMed
16.
go back to reference Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17(3):341–345CrossRefPubMed Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17(3):341–345CrossRefPubMed
17.
go back to reference Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ (2005) A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Pathol 58(5):493–499CrossRefPubMed Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ (2005) A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Pathol 58(5):493–499CrossRefPubMed
18.
go back to reference Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMed Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMed
19.
go back to reference Hout AH, Ouweland AM, Luijt RB, Gille HJ, Bodmer D, Bruggenwirth H, Mulder IM, Vlies PV, Elfferich P, Huisman MT et al (2006) A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat Hout AH, Ouweland AM, Luijt RB, Gille HJ, Bodmer D, Bruggenwirth H, Mulder IM, Vlies PV, Elfferich P, Huisman MT et al (2006) A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat
20.
go back to reference Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57CrossRefPubMed Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57CrossRefPubMed
21.
go back to reference de Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P et al (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 106(4):588–593CrossRefPubMed de Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P et al (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 106(4):588–593CrossRefPubMed
22.
go back to reference Liede A, Narod SA (2002) Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20(6):413–424CrossRefPubMed Liede A, Narod SA (2002) Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20(6):413–424CrossRefPubMed
23.
go back to reference Ho GH, Phang BH, Ng IS, Law HY, Soo KC, Ng EH (2000) Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years. Cancer 89(4):811–816CrossRefPubMed Ho GH, Phang BH, Ng IS, Law HY, Soo KC, Ng EH (2000) Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years. Cancer 89(4):811–816CrossRefPubMed
24.
go back to reference Takeda M, Ishida T, Ohnuki K, Suzuki A, Sakayori M, Ishioka C, Nomizu T, Noguchi S, Matsubara Y, Ohuchi N (2004) Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan. Breast Cancer 11(1):30–32PubMedCrossRef Takeda M, Ishida T, Ohnuki K, Suzuki A, Sakayori M, Ishioka C, Nomizu T, Noguchi S, Matsubara Y, Ohuchi N (2004) Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan. Breast Cancer 11(1):30–32PubMedCrossRef
25.
go back to reference Shinohara A, Ogawa H, Ogawa T (1992) Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 69(3):457–470CrossRefPubMed Shinohara A, Ogawa H, Ogawa T (1992) Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 69(3):457–470CrossRefPubMed
26.
go back to reference Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A (2004) DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep 5(10):989–993CrossRefPubMed Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A (2004) DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep 5(10):989–993CrossRefPubMed
27.
go back to reference Rudkin TM, Foulkes WD (2005) BRCA2: breaks, mistakes and failed separations. Trends Mol Med 11(4):145–148CrossRefPubMed Rudkin TM, Foulkes WD (2005) BRCA2: breaks, mistakes and failed separations. Trends Mol Med 11(4):145–148CrossRefPubMed
28.
go back to reference Somasundaram K (2003) Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair–perhaps through transcription. J Cell Biochem 88(6):1084–1091CrossRefPubMed Somasundaram K (2003) Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair–perhaps through transcription. J Cell Biochem 88(6):1084–1091CrossRefPubMed
29.
go back to reference Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185(4154):862–864CrossRefPubMed Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185(4154):862–864CrossRefPubMed
30.
go back to reference Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60(5):1013–1020PubMed Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60(5):1013–1020PubMed
Metadata
Title
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
Authors
Dewajani Purnomosari
Gerard Pals
Artanto Wahyono
Teguh Aryandono
Tjakra W. Manuaba
Samuel J. Haryono
Paul J. van Diest
Publication date
01-12-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9493-4

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine